Delivery Order SPE2DR25D2104-SPE2DR26F3QWF
- Not listed
- The Defense Logistics Agency awarded a $10,547.87 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count). This is a competitively awarded, firm fixed-price delivery order with no set-aside designation, due for completion by August 5, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $12,545.94 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $36,573.09 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count) on November 10, 2025, with completion targeted for November 12, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and is performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units) with a ceiling value of $1,089.41. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement process. The order is set to reach completion by November 4, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) valued at $19,488.02. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 19, 2025, with performance occurring at the vendor's Conshohocken, Pennsylvania headquarters. The contract carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for Trelegy Ellipta 100-62.5-25 60S inhalers, with a contract ceiling value of $18,305.12 and ultimate completion date of October 21, 2025. This competitively awarded, non-set-aside delivery order represents a pharmaceutical supply transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global...
- The Defense Logistics Agency awarded a delivery order valued at $7,796.67 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on November 24, 2025, with completion targeted for November 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Trelegy Ellipta is a combination maintenance inhaler used to treat chronic obstructive pulmonary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) with a ceiling value of $9,375.10. This is a firm fixed price delivery order with no set-aside designation, issued as a competitive award under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $1,492.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count units). This is a non-competitive delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order valued at $5,101.16 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on December 1, 2025, with a completion deadline of December 2, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and represents a continuation of the company's pharmaceutical supply services to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3QWFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count packages) with a ceiling value of $13,819.64. This firm fixed-price delivery order is non-competitive and represents a call against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The ultimate completion date is December 9, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. TRELEGY ELLIPTA is a combination respiratory medication used to treat chronic obstructive pulmonary disease. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications and medical supplies across therapeutic domains to support military healthcare systems, the Defense Health Agency, and other federal customers. This delivery order exemplifies the company's role in fulfilling routine pharmaceutical supply needs through the DLA's global pharmaceutical support vehicle, ensuring consistent access to brand-name medications for military and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.8k | 12/7/25 |